WO2022089476A1 - 一种生物液体样本中病原体的核黄素光化学灭活方法 - Google Patents

一种生物液体样本中病原体的核黄素光化学灭活方法 Download PDF

Info

Publication number
WO2022089476A1
WO2022089476A1 PCT/CN2021/126678 CN2021126678W WO2022089476A1 WO 2022089476 A1 WO2022089476 A1 WO 2022089476A1 CN 2021126678 W CN2021126678 W CN 2021126678W WO 2022089476 A1 WO2022089476 A1 WO 2022089476A1
Authority
WO
WIPO (PCT)
Prior art keywords
liquid sample
riboflavin
biological liquid
light
pathogens
Prior art date
Application number
PCT/CN2021/126678
Other languages
English (en)
French (fr)
Inventor
刘忠
尹云弟
李玲
徐海霞
龚丽
Original Assignee
中国医学科学院输血研究所
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 中国医学科学院输血研究所 filed Critical 中国医学科学院输血研究所
Priority to US18/034,643 priority Critical patent/US20230321288A1/en
Publication of WO2022089476A1 publication Critical patent/WO2022089476A1/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
    • A61L2/08—Radiation
    • A61L2/10—Ultraviolet radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A61L2/0029—Radiation
    • A61L2/0047—Ultraviolet radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A61L2/0029—Radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
    • A61L2/0088—Liquid substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2101/00—Chemical composition of materials used in disinfecting, sterilising or deodorising
    • A61L2101/32—Organic compounds
    • A61L2101/44—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2202/00—Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
    • A61L2202/20—Targets to be treated
    • A61L2202/22—Blood or products thereof
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the invention belongs to the technical field of pathogen inactivation, in particular to a riboflavin photochemical inactivation method for pathogens in biological liquid samples.
  • pathogens are present in biological fluid samples that need to be inactivated.
  • biological fluid samples For example, in blood products, blood-borne pathogens, including viruses, bacteria, protozoa, and spirochetes, are often introduced during collection and transportation.
  • the development of pathogen inactivation technology can effectively reduce the risk of blood transfusion infection.
  • the promising blood pathogen inactivation technologies mainly include psoralen and riboflavin, which can be used for plasma, platelet and red blood cell pathogen inactivation.
  • Psoralen may be genotoxic and therefore needs to be removed after use.
  • Riboflavin (vitamin B2) is a natural vitamin necessary for the human body. Its decomposition products are widely present in human blood and tissues, and have natural photochemical reactions. They do not need to be removed after use, and are widely used in blood component pathogen inactivation. middle.
  • the Chinese patent application "CN201910975223.2 Equipment and method for inactivating blood component pathogens by riboflavin photochemical method” proposes a method for inactivating pathogens in blood by riboflavin photochemical method, and the conditions for inactivation are carried out.
  • the optimal conditions disclosed in the patent application are to use 309nm-313nm narrow-spectrum ultraviolet light, the best illumination time range is 5-40min, and the illumination energy range is 0.4J/ml-3J/ml.
  • the inactivation effect on pathogens is still not ideal, and other components in the blood product are still damaged to a certain extent. It is for the above reasons.
  • the riboflavin pathogen inactivation system is used in Europe and other countries to inactivate pathogens in blood, it has not yet been approved by the FDA in the United States.
  • the present invention provides a riboflavin photochemical inactivation method for pathogens in biological liquid samples, the purpose of which is: by optimizing the wavelength range of illumination, the riboflavin Photochemical inactivation methods are more effective in inactivating pathogens and cause less damage in blood components.
  • a method for photochemical inactivation of riboflavin in a biological liquid sample comprising the steps of adding riboflavin to the biological liquid sample and irradiating the biological liquid sample with light, wherein the light is in a wavelength range selected from 360-370 nm and/or 390 nm -Narrow spectrum UV light in the range of 400nm.
  • the light is a narrow-spectrum ultraviolet light with a wavelength range selected from the range of 390-400 nm.
  • the light is ultraviolet light with a peak at 395 nm.
  • the light irradiation time of the biological liquid sample is 3-30min, and the light energy range is 0.2-5J/ml.
  • the light irradiation time of the biological liquid sample is 3-4.9min, and the light energy range is 0.2-0.39J/ml.
  • the amount of riboflavin added in the biological fluid sample is 40-60 ⁇ M.
  • the amount of riboflavin added in the biological fluid sample is 50 ⁇ M.
  • the biological fluid sample is a blood product, blood product, cell product or tumor cell sample.
  • the blood product is whole blood, leukopenic whole blood, packaged red blood cells, manual platelets, apheresis platelets, plasma or cryoprecipitate.
  • the present invention improves the method for photochemical inactivation of pathogens in biological fluid samples (such as blood products) by riboflavin, and the light wavelength is preferred.
  • the illumination in the preferred wavelength range of the present invention has a better inactivation effect on pathogens.
  • the narrow-spectrum ultraviolet light in this wavelength range can be used to inactivate organisms in a shorter light time and lower light intensity. The liquid sample undergoes pathogen inactivation, thereby reducing light damage to other components in the biological liquid sample.
  • the method of the invention is suitable for inactivation of pathogens in blood products, decontamination treatment of various biological liquid samples, treatment of severe clinical infection and tumor patients, etc., and is widely used.
  • Fig. 1 adopts the inactivation effect of narrow-spectrum ultraviolet light of different wavelength ranges on Escherichia coli in the method for photochemical inactivation of pathogens in blood products by riboflavin;
  • Fig. 2 Inactivation effect of narrow-spectrum ultraviolet light with a wavelength of 395 ⁇ 5 nm and narrow-spectrum ultraviolet light with a wavelength of 309-313 nm on Staphylococcus aureus in platelets.
  • the specific operation and device of the method for photochemically inactivating pathogens in a biological liquid sample by riboflavin in the present invention can be performed with reference to the content disclosed in the prior art.
  • the specific operations and devices in the following examples are consistent with the methods and devices disclosed in Chinese patent application "CN201910975223.2 Device and method for inactivating blood component pathogens by riboflavin photochemical method", the differences are the wavelength range of illumination, illumination time , light energy and riboflavin concentration were changed.
  • a series of LED lamp beads in a wavelength range are selected to irradiate the plasma of healthy blood donors containing 50 ⁇ M riboflavin, the illumination time is 15 min, and the illumination intensity is 1 W. E. coli growth in blood products was then detected by the Reed-Muench method.
  • LED lamp beads with wavelengths of 365 ⁇ 5nm and wavelengths of 395 ⁇ 5nm were used in the riboflavin photochemical pathogen inactivation system. It has good pathogen inactivation effect on Escherichia coli.
  • LED lamp beads with a wavelength of 395 ⁇ 5nm and fluorescent tubes with a wavelength of 309-313nm were selected to irradiate the apheresis platelets containing 50 ⁇ M riboflavin. 5nm) and 9W (309-313nm).
  • the growth of Staphylococcus aureus in blood products was then detected by the Reed-Muench method.
  • the light dose of 309-313 nm narrow-spectrum ultraviolet light and the light dose of 395 ⁇ 5 nm narrow-spectrum ultraviolet light are compared under the same inactivation effect.
  • riboflavin physiological saline solution (CAS: 83-88-5; purchased from Sigma-Aldrich, St. Louis, Missouri, USA) into the bacterial plasma suspension, the final riboflavin concentration is 50 ⁇ mol/L .
  • the light dose of 309-313nm fluorescent tube is 9.76J/mL, and the illumination time is 30 minutes.
  • the 395 ⁇ 5nm LED lamp bead light dose is 1.25J/mL, and the illumination time is 10 minutes. Two groups of experimental samples were carried out in parallel for 6 groups.
  • the experimental sample and the control sample are serially diluted by 10 1 -10 6 ;
  • the narrow-spectrum ultraviolet light in the preferred wavelength range of the present invention has better inactivation effect on pathogens and less damage to other components in biological fluid samples (eg, blood products).
  • the narrow-spectrum ultraviolet light in the preferred wavelength range of the invention it is possible to select shorter illumination time and lower illumination energy, thereby further reducing the damage of illumination to other components in biological fluid samples (eg, blood products).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)

Abstract

本发明属于病原体灭活技术领域，具体涉及一种生物液体样本中病原体的核黄素光化学灭活方法。针对现有的核黄素病原体灭活方法中存在的问题，本发明的技术方案是一种生物液体样本中病原体的核黄素光化学灭活方法：包括向生物液体样本中加入核黄素并用光辐射生物液体样本的步骤，所述光为波长范围选自360-370nm和/或390-400nm范围内的窄谱紫外光。本发明还进一步优选了光照时间、光照强度和核黄素浓度等参数。采用本发明的技术方案，能够达到优良的病原体灭活效果，且对生物液体样本中其他成分的损伤小。

Description

一种生物液体样本中病原体的核黄素光化学灭活方法 技术领域
本发明属于病原体灭活技术领域，具体涉及一种生物液体样本中病原体的核黄素光化学灭活方法。
背景技术
在医学或生物学中，常常出现生物液体样本中存在病原体需要灭活的情况。例如在血液制品中，采集、转运等过程中常常引入血传播病原体，这些血传播病原体包括病毒、细菌、原虫和螺旋体等。
随着血液病原体检测技术的发展，输血感染风险大大降低，但病原体检测窗口期依然存在、目前常规检测方法不能覆盖所有已知经血传播病原体。新发、再发经血传播病原体依旧威胁着输血安全，特别是血小板(PLT)常规储存在20-24℃条件下，细菌污染风险更高，持续稳定的血源性细菌污染成为了对血液供应机构威胁最大的因素。
发展病原体灭活技术可以有效降低输血感染风险，目前具有发展前景的血液病原体灭活技术主要有补骨脂素和核黄素，均可用于血浆、血小板和红细胞病原体灭活。补骨脂素可能存在基因毒性，因此使用后需要去除。而核黄素(维生素B2)是人体必须的天然维生素，其分解产物本身广泛存在于人体血液和组织中，并且具有天然的光化学反应，使用后不需去除，被广泛应用于血液成分病原体灭活中。
例如，中国专利申请“CN201910975223.2利用核黄素光化学法灭活血液成分病原体的设备及方法”中提出了一种核黄素光化学法灭活血液中病原体的方法，且对灭活的条件进行了优选。该专利申请中公开的较优条件为采用309nm-313nm窄谱紫外光，光照时间范围5-40min为最佳，光照能量范围0.4J/ml-3J/ml为最佳。但是，在该条件下，对病原体的灭活效果仍然不够理想，且对血液产品中的其它成分仍然具有一定的损伤。正是由于上述原因。虽然核黄素病原体灭活系统灭活血液中病原体在欧洲等国家使用，然而其在美国尚未得到FDA批准。
发明内容
针对现有的核黄素病原体灭活方法中存在的问题，本发明提供一种生物液体样本中病原体的核黄素光化学灭活方法，其目的在于：通过优化光照的 波长范围，使得核黄素光化学灭活方法对病原体的灭活效果更好，且对血液成分中造成的损伤更低。
一种生物液体样本中病原体的核黄素光化学灭活方法，包括向生物液体样本中加入核黄素并用光辐射生物液体样本的步骤，所述光为波长范围选自360-370nm和/或390-400nm范围内的窄谱紫外光。
优选的，光为波长范围选自390-400nm范围内的窄谱紫外光。
优选的，光为波峰为395nm的紫外光。
优选的，光辐射生物液体样本的光照时间为3-30min，光照能量范围为0.2-5J/ml。
优选的，光辐射生物液体样本的光照时间为3-4.9min，光照能量范围为0.2-0.39J/ml。
优选的，核黄素在生物液体样本中的加入量为40-60μM。
优选的，核黄素在生物液体样本中的加入量为50μM。
优选的，生物液体样本为血液产品、血液产品、细胞产品或肿瘤细胞样本。
优选的，血液产品为全血、白细胞减少的全血、包装红细胞、手工血小板、单采血小板、血浆或冷沉淀。
本发明对核黄素光化学灭活生物液体样本(例如血液产品)中的病原体的方法进行改进，优选了光照波长。在相同的光照时间和光照强度的条件下，本发明优选的波长范围的光照对病原体具有更好的灭活效果。此外，由于该波长范围内的光照对病原体的灭活效果更好，因而在实际操作中，选用该波长范围内的窄谱紫外光可在更短的光照时间和更低的光照强度下对生物液体样本进行病原体灭活，从而降低光照对生物液体样本中的其他成分的损伤。
本发明的方法适用于血液产品中的病原体灭活、各种生物液体样本的去污处理、临床重度感染和肿瘤患者的治疗等，应用广泛。
显然，根据本发明的上述内容，按照本领域的普通技术知识和惯用手段，在不脱离本发明上述基本技术思想前提下，还可以做出其它多种形式的修改、替换或变更。
以下通过实施例形式的具体实施方式，对本发明的上述内容再作进一步的详细说明。但不应将此理解为本发明上述主题的范围仅限于以下的实例。凡基于本发明上述内容所实现的技术均属于本发明的范围。
附图说明
图1核黄素光化学灭活血液产品中的病原体的方法中采用不同波长范围的窄谱紫外光对大肠杆菌的灭活效果；
图2波长为395±5nm的窄谱紫外光和波长范围为309-313nm的窄谱紫外光对血小板中的金黄色葡萄球菌的灭活效果。
具体实施方式
下面通过具体的实施例对本发明的技术方案作进一步的说明。
本发明中核黄素光化学灭活生物液体样本中的病原体的方法的具体操作及装置可参考现有技术中已公开的内容进行。以下实施例中的具体操作和装置采用与中国专利申请“CN201910975223.2利用核黄素光化学法灭活血液成分病原体的设备及方法”中公开的方法和装置一致，区别在于光照波长范围、光照时间、光照能量和核黄素的浓度等进行了改变。
实施例1
本实施例选择了一系列波长范围的LED灯珠对含有50μM核黄素的健康献血者的血浆进行照射，光照时间为15min，光照强度为1W。然后通过Reed-Muench法检测血液产品中的大肠杆菌生长量。
结果如图1所示，相同光照时间和光照强度下，在一系列的窄谱紫外光中，波长为365±5nm和波长为395±5nm的LED灯珠在核黄素光化学病原体灭活系统中对大肠杆菌有较好的病原体灭活效果。
实施例2
本实施例选择了波长为395±5nm的LED灯珠和波长为309-313nm的荧光灯管对含有50μM核黄素的单采血小板进行照射，光照时间均为30min，光照强度分别为1W(395±5nm)和9W(309-313nm)。然后通过Reed-Muench法检测血液产品中的金黄色葡萄球菌的生长量。
结果如图2所示，图中还给出了未通过核黄素光化学灭活的对照实验组的数据。从图中可以看出，虽然395±5nm的LED灯珠和波长为309-313nm的荧光灯管都能够对金黄色葡萄球菌进行灭活，但是在相同光照时间和光照强度下，395±5nm的LED灯珠比波长为309-313nm的荧光灯管的灭活效果更好。
对比三组实验中血小板样品的性质及成分含量，结果如下：
表1 血小板保存质量
检测项目 395±5nm 309-313nm 对照(无光照)
PH 7.45±0.01 7.26 7.53
Na+mmol/L 153.6±0.49 151 152
K+mmol/L 2.7±0 3 2.6
Glummol/L 26.3±0.09 23.6 26
Lacmmol/L 9.24±0.08 10.6 8.1
HCO3-mmol/L 8.54±0.22 8.5 10
HCO3std 15.26±0.15 12.2 17.2
TCO2 8.94±0.22 9.1 10.4
PLT 714.2±6.49 297 717
PDW 10.84±0.16 17.3 10.9
MPV 9.5±0 12.1 9.4
P-LCR 21.2±0.2 36.7 20.7
PCT 0.68±0.01 0.36 0.68
从表1中的数据可以看到，在利用核黄素光化学法对血小板进行病原体灭活后，各项性质和成分含量的参数与未光照的对照组均有一定的偏离，但是，采用395±5nm的LED灯珠光照对各项性质和成分含量的影响明显小于采用309-313nm的荧光灯管光照对各项性质和成分含量的影响，可见，395±5nm的光照对血小板样品的损伤显著更小。
实施例3
本实施例对相同灭活效果下，采用309-313nm窄谱紫外光的光剂量和395±5nm窄谱紫外光的光剂量进行对比。
具体实验步骤为：
1、取一袋健康献血者血浆(获得当地伦理委员会支持)150ml,加入10uL金黄色葡萄球菌培养液，获得大约4-5log的细菌血浆悬浮液；
2、取9mL细菌血浆悬浮液与1mL生理盐水混合作为对照，放置于4℃冰箱中；
3、然后将500μmol/L的核黄素生理盐水溶液(CAS:83-88-5；购自美国密苏里州圣路易斯Sigma-Aldrich公司)加入细菌血浆悬浮液中，最终核黄素浓度为50μmol/L。
4、分别取300uL加核黄素的细菌血浆悬液转移到无菌24孔板中(孔直径为1.5cm)，然后分别暴露于9W 309-313nm荧光灯管(UVB窄带PL-L/PL-S,飞利浦,阿姆斯特丹,荷兰)和1W 395±5nm LED灯珠下，在温度控制的环境中(20-24℃)照射样本。
309-313nm荧光灯管光剂量为9.76J/mL，光照时间为30分钟。395±5nm LED灯珠光剂量为1.25J/mL，光照时间为10分钟。两组实验样本各平行进行6组。
5、光照结束后实验样本和对照样本连续稀释10 1-10 6；
6、每个稀释后的样品取100μL加入无菌板中心，每个稀释度样本重复接种8次，测定细菌生长量。
7、37℃生化培养箱(中国上海景洪SHP-080)培养24-48h后，观察各孔细菌生长情况并记录，采用Reed-Muench法计算细菌滴度。
实验结果表明：采用309-313nm紫外光较高光剂量进行照射后与采用395±5nm紫外光较低光剂量进行照射后，309-313nm和395±5nm细菌生长量分别为2.01±1.99log和2.22±1.80log，无统计学差异(P＝0.568)，即对病原体的灭活效果相当。
从上述实施例中可以看到，本发明优选的波长范围的窄谱紫外光对病原体的灭活效果更好，且对生物液体样本(例如血液产品)中的其他成分的损伤更小。此外，采用发明优选的波长范围的窄谱紫外光，能够选择更短的光照时间和更低的光照能量，从而进一步降低光照对生物液体样本(例如血液产品)中的其他成分的损伤。

Claims (9)

  1. 一种生物液体样本中病原体的核黄素光化学灭活方法，包括向生物液体样本中加入核黄素并用光辐射生物液体样本的步骤，其特征在于：所述光为波长范围选自360-370nm和/或390-400nm范围内的窄谱紫外光。
  2. 按照权利要求1所述的一种生物液体样本中病原体的核黄素光化学灭活方法，其特征在于：所述光为波长范围选自390-400nm范围内的窄谱紫外光。
  3. 按照权利要求2所述的一种生物液体样本中病原体的核黄素光化学灭活方法，其特征在于：所述光为波峰为395nm的紫外光。
  4. 按照权利要求1所述的一种生物液体样本中病原体的核黄素光化学灭活方法，其特征在于：所述光辐射生物液体样本的光照时间为3-30min，光照能量范围为0.2-5J/ml。
  5. 按照权利要求4所述的一种生物液体样本中病原体的核黄素光化学灭活方法，其特征在于：所述光辐射生物液体样本的光照时间为3-4.9min，光照能量范围为0.2-0.39J/ml。
  6. 按照权利要求1所述的一种生物液体样本中病原体的核黄素光化学灭活方法，其特征在于：所述核黄素在生物液体样本中的加入量为40-60μM。
  7. 按照权利要求6所述的一种生物液体样本中病原体的核黄素光化学灭活方法，其特征在于：所述核黄素在生物液体样本中的加入量为50μM。
  8. 按照权利要求1所述的一种生物液体样本中病原体的核黄素光化学灭活方法，其特征在于：所述生物液体样本为血液产品、细胞产品或肿瘤细胞样本。
  9. 按照权利要求8所述的一种生物液体样本中病原体的核黄素光化学灭活方法，其特征在于：所述血液产品为全血、白细胞减少的全血、包装红细胞、手工血小板、单采血小板、血浆或冷沉淀。
PCT/CN2021/126678 2020-10-30 2021-10-27 一种生物液体样本中病原体的核黄素光化学灭活方法 WO2022089476A1 (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US18/034,643 US20230321288A1 (en) 2020-10-30 2021-10-27 Riboflavin photochemical treatment (rpt)-based inactivation method of pathogens in biological liquid sample

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202011197064.7A CN112316166B (zh) 2020-10-30 2020-10-30 一种生物液体样本中病原体的核黄素光化学灭活方法
CN202011197064.7 2020-10-30

Publications (1)

Publication Number Publication Date
WO2022089476A1 true WO2022089476A1 (zh) 2022-05-05

Family

ID=74323788

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/126678 WO2022089476A1 (zh) 2020-10-30 2021-10-27 一种生物液体样本中病原体的核黄素光化学灭活方法

Country Status (3)

Country Link
US (1) US20230321288A1 (zh)
CN (1) CN112316166B (zh)
WO (1) WO2022089476A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115948380A (zh) * 2023-03-10 2023-04-11 北京大有天弘科技有限公司 一种免疫细胞的处理方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112316166B (zh) * 2020-10-30 2022-07-12 中国医学科学院输血研究所 一种生物液体样本中病原体的核黄素光化学灭活方法
CN114225067B (zh) * 2021-12-22 2024-01-26 中国医学科学院输血研究所 一种血液病原体灭活方法
CN114366831A (zh) * 2022-01-10 2022-04-19 南京双威生物医学科技有限公司 一种基于核黄素光化学法的血浆病原体灭活处理方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003094979A1 (en) * 2002-05-06 2003-11-20 Gambro, Inc. Method for preventing damage to or rejuvenating a cellular blood component using mitochondrial enhancer
CN202844169U (zh) * 2012-10-25 2013-04-03 山东省血液中心 一种灭活血小板中微生物的血小板保存装置
CN110585456A (zh) * 2019-09-25 2019-12-20 赛克赛斯生物科技股份有限公司 生物材料的病毒灭活方法、处理方法和应用
CN110639038A (zh) * 2019-10-14 2020-01-03 中国医学科学院输血研究所 利用核黄素光化学法灭活血液成分病原体的设备及方法
CN111770789A (zh) * 2017-12-29 2020-10-13 塞鲁斯公司 用于处理生物流体的系统和方法
CN112316166A (zh) * 2020-10-30 2021-02-05 中国医学科学院输血研究所 一种生物液体样本中病原体的核黄素光化学灭活方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020015662A1 (en) * 2000-06-15 2002-02-07 Hlavinka Dennis J. Inactivation of contaminants using photosensitizers and pulsed light
CN109966574A (zh) * 2016-02-02 2019-07-05 汪相伯 一种基于核黄素光化学法的血液制品处理系统
AU2020372904A1 (en) * 2019-10-31 2022-06-02 Hemanext Inc. Anaerobic blood storage and pathogen inactivation method

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003094979A1 (en) * 2002-05-06 2003-11-20 Gambro, Inc. Method for preventing damage to or rejuvenating a cellular blood component using mitochondrial enhancer
CN202844169U (zh) * 2012-10-25 2013-04-03 山东省血液中心 一种灭活血小板中微生物的血小板保存装置
CN111770789A (zh) * 2017-12-29 2020-10-13 塞鲁斯公司 用于处理生物流体的系统和方法
CN110585456A (zh) * 2019-09-25 2019-12-20 赛克赛斯生物科技股份有限公司 生物材料的病毒灭活方法、处理方法和应用
CN110639038A (zh) * 2019-10-14 2020-01-03 中国医学科学院输血研究所 利用核黄素光化学法灭活血液成分病原体的设备及方法
CN112316166A (zh) * 2020-10-30 2021-02-05 中国医学科学院输血研究所 一种生物液体样本中病原体的核黄素光化学灭活方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115948380A (zh) * 2023-03-10 2023-04-11 北京大有天弘科技有限公司 一种免疫细胞的处理方法

Also Published As

Publication number Publication date
CN112316166A (zh) 2021-02-05
US20230321288A1 (en) 2023-10-12
CN112316166B (zh) 2022-07-12

Similar Documents

Publication Publication Date Title
WO2022089476A1 (zh) 一种生物液体样本中病原体的核黄素光化学灭活方法
US11951217B2 (en) Inactivation of pathogens in ex vivo blood products in storage bags using visible light
KR950006931B1 (ko) 생물학적 유체를 멸균하기 위한 자외선 조사장치
US20170232163A1 (en) Blood bag system and process for the inactivation of pathogens in platelet concentrates by use of the blood bag system
CA2089005C (en) Method for inactivating pathogens in a body fluid
US8753807B2 (en) Method for microbes depletion in human blood or full serum using antimicrobial photodynamic laser therapy
RU2466742C2 (ru) Способ инактивирования патогенов в донорской крови, плазме крови или концентратах эритроцитов в гибких контейнерах с помощью встряхивания
CN112640923B (zh) 姜黄精油作为紫外杀菌增效剂的应用
Shang et al. Repression of photoreactivation and dark repair of coliform bacteria by TiO2-modified UV-C disinfection
CN112568243B (zh) 一种紫外杀菌增效剂及其联合紫外进行杀菌的方法
JP2004528882A (ja) 単色液体処理システム
AU779193B2 (en) Methods of inactivating pathogens using broad-spectrum pulsed light
US20200253195A1 (en) Apparatus and Methods for Irradiating Organ Perfusates
Gugerell et al. Viral safety of APOSECTM: a novel peripheral blood mononuclear cell derived-biological for regenerative medicine
JPH0547222B2 (zh)
CN112450229B (zh) 植物精油类紫外杀菌增效剂及其联合紫外进行杀菌的方法
CN112602707B (zh) 一种紫外杀菌增效剂癸二酸及其应用
NL2033728B1 (en) Blood pathogen inactivation method
Margolis‐Nunno et al. Psoralen‐mediated virus photoinactivation in platelet concentrates: enhanced specificity of virus kill in the absence of shorter UVA wavelengths
CN112655708A (zh) 一种紫外杀菌增效剂(s)-2-羟基-4-甲基戊酸及其应用
CN105765064A (zh) 用于灭活医疗器械上包含rna和dna的病毒的方法以及实施该方法的设备
Oliveira et al. Photodynamic Therapy in the Extracellular Matrix of Mouse Lungs: Preliminary Results of an Alternative Tissue Sterilization Process
RU2558432C2 (ru) Способ инактивации патогенов
CN116676278A (zh) 血小板病毒灭活方法及曲克芦丁在血小板病毒灭活的应用
CN113907094A (zh) 一种紫外杀菌增效剂法国丝柏精油及其应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21885203

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21885203

Country of ref document: EP

Kind code of ref document: A1